We would like to inform you that the Board of Directors has at its meeting held today i.e. 30.05.2026 approved the appointment of Mr. Rajinder Singh Manku as an additional director in the ....
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Panacea Biotec reported audited financial results for Q4 and FY ended March 2026. Standalone revenue grew 33% to ₹41,349 Lakh, but net loss widened to ₹2,988 Lakh (vs ₹1,523 Lakh prior year). Consolidated revenue rose 13% to ₹65,677 Lakh with net loss improving to ₹716 Lakh from ₹872 Lakh. The board skipped dividend for FY 2025-26 due to losses. Mr. Rajinder Singh Manku was appointed as additional non-executive independent director for 5 years starting July 1, 2026, subject to shareholder approval. The auditors issued an unmodified opinion. Notes highlight going concern uncertainty due to negative retained earnings of ₹21,782 Lakh, though the Group's consolidated retained earnings remain positive at ₹77,605 Lakh.
Revenue growth is positive but persistent losses and negative standalone retained earnings raise concerns about financial stability. The dividend skip and going concern note may pressure sentiment despite operational revenue growth. The new independent director appointment strengthens board independence pending shareholder approval.